par Boland, Lidvine;Devresse, Arnaud;Monchaud, Caroline;Briol, Sébastien;Belaiche, Stéphanie;Giguet, Baptiste;Couzi, Lionel;Thaunat, Olivier;Esposito, Laure;Meszaros, Magdalena;Roussoulieres, Ana
;Haufroid, Vincent;Le Meur, Yannick;Lemaitre, Florian
Référence Transplant international, 37, 12360
Publication Publié, 2024
![](/vufind/images/ULB/publications_list.png)
Référence Transplant international, 37, 12360
Publication Publié, 2024
Article révisé par les pairs
Résumé : | Nirmatrelvir/ritonavir is a promising option for preventing severe COVID-19 in solid organ transplant recipients with SARS-CoV-2 infection. However, concerns have arisen regarding potential drug interactions with calcineurin inhibitors (CNI). This two-phase multicentre retrospective study, involving 113 patients on tacrolimus and 13 on cyclosporine A, aimed to assess the feasibility and outcomes of recommendations issued by The French societies of transplantation (SFT) and pharmacology (SFPT) for CNI management in this context. The study first evaluated adherence to recommendations, CNI exposure, and clinical outcomes. Notably, 96.5% of patients on tacrolimus adhered to the recommendations, maintaining stable tacrolimus trough concentrations (C0) during nirmatrelvir/ritonavir treatment. After reintroduction, most patients experienced increased C0, with 42.9% surpassing 15 ng/mL, including three patients exceeding 40 ng/mL. Similar trends were observed in cyclosporine A patients, with no COVID-19-related hospitalizations. Moreover, data from 22 patients were used to refine the reintroduction strategy. Modelling analyses suggested reintroducing tacrolimus at 50% of the initial dose on day 8, and then at 100% from day 9 as the optimal approach. In conclusion, the current strategy effectively maintains consistent tacrolimus exposure during nirmatrelvir/ritonavir treatment, and a stepwise reintroduction of tacrolimus may be better suited to the low CYP3A recovery. |